Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024,
Eloxx Pharmaceuticals, Inc.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of Eloxx Pharmaceuticals, Inc., effective
at the opening of the trading session on April 1, 2024.
On April 11, 2023, Nasdaq Listing Qualifications staff (Staff) notified
Eloxx Pharmaceuticals, Inc. (Company) that it determined to delist the
Company based on its noncompliance with Rule 5550(b)(2). On April 18,
2023, the Company exercised its right to appeal the Staff determination
to the Listing Qualifications Hearings Panel (Panel) pursuant to Rule
5815.  A Panel hearing was held on May 18, 2023.  On June 2, 2023, the
Panel issued a decision to continue listing the Company securities
provided certain conditions were met.  On October 12, 2023, the Panel
issued a decision to delist the shares of the Company due to the Company
failure to regain compliance with Rule 5550(b)(2). On October 26, 2023,
the Company exercised its right to appeal the Panel decision to the
Nasdaq Listing and Hearing Review Council (Council) pursuant to Rule
5820(a).  On December 21, 2023, the Council issued a decision that
affirmed the Panel decision to delist the Company securities.  On
February 7, 2024, the Company was provided notice that the Nasdaq Board
of Directors declined to call the Council decision for review pursuant
to Rule 5825(a). The Staff determination to delist the Company units
and rights became final on February 7, 2024.